Browse

S-Space

Browsing "Cancer Research Institute (암연구소)" by Title 

전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 20 of 206

Issue Date Title / Author(s) / CitationFileAltmetrics
2016-03
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
DOI
2011-01
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinonna harboring EGFR mutations
DOI
2014-11
A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group
DOI
2019-10
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
DOI
2019-01
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
DOI
2015-02
A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo
DOI
2014-01
A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy
view fileDOI
2015-05
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
DOI
2015-10
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer
DOI
2017-02
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
view fileDOI
2019-07
Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib

Kim, Seulki; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Alm, Yong-Oon; Keam, Bhumsuk; Heo, Dae Seog

Cancer Research and Treatment, Vol.51 No.3, pp.951-962

view fileDOI
2017-11
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
DOI
2016-04
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
DOI
2014-12
Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score
DOI
2019-07
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
DOI
2012-03
Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients
DOI
2016-03
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
DOI
2016-05
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
DOI
2017-02
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
DOI
2016-03
Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: A phase II global study
DOI
1 2 3 4 5 611

Seoul National University Library, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea TEL: 02-880-5567 Email: s-space@snu.ac.kr youtube

RSS 1.0 RSS 2.0 Atom

Hello

Browse

News About S-Space Seoul National University Library LOGIN